Symptomatic avascular necrosis: An understudied risk factor for acute care utilization by patients with SCD

Southern Medical Journal

Volumn 109, Issue 9, 2016, Pages 519-524

  Yu, Tiffany ^a   Campbell, Timothy ^a   Ciuffetelli, Isabella ^a   Haywood, Carlton ^a   Carroll, Christopher Patrick ^a   Resar, Linda ^a   Strouse, John J ^a   Lanzkron, Sophie ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

hospitalization; Key Words avascular necrosis; osteonecrosis; sickle cell disease; utilization

Indexed keywords

HEMOGLOBIN; HYDROXYUREA;

ACUTE CHEST SYNDROME; ADULT; AGED; ARTICLE; AVASCULAR NECROSIS; BLOOD TRANSFUSION; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; FEMORAL HEAD; GENOTYPE; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITAL ADMISSION; HUMAN; HUMERAL HEAD; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RISK FACTOR; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; TREATMENT DURATION; VERY ELDERLY; ANEMIA, SICKLE CELL; CASE CONTROL STUDY; COMPLICATION; INTENSIVE CARE; MIDDLE AGED; OSTEONECROSIS; RETROSPECTIVE STUDY; UTILIZATION; YOUNG ADULT;

ADULT; AGED; ANEMIA, SICKLE CELL; CASE-CONTROL STUDIES; CRITICAL CARE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEONECROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84985898465     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.14423/SMJ.0000000000000512     Document Type: Article

References (28)

1. Blinder M, Vekeman F, Sasane M, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer 2013; 60: 828-835
2. Carroll CP, Haywood C Jr, Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med 2011; 6: 248-255
3. Carroll CP, Haywood C Jr, Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009; 84: 666-670
4. Epstein K, Yuen E, Riggio JM, et al. Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc 2006; 98: 1109-1113
5. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005; 84: 363-376
6. Akinyoola AL, Adediran IA, Asaleye CM, et al. Risk factors for osteonecrosis of the femoral head in patients with sickle cell disease. Int Orthop 2009; 33: 923-926
7. Akinyoola AL, Adediran IA, Asaleye CM. Avascular necrosis of the femoral head in sickle cell disease in Nigeria: a retrospective study. Niger Postgrad Med J 2007; 14: 217-220
8. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 325: 1476-1481
9. Powars DR, Hiti A, Ramicone E, et al. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol 2002; 70: 206-215
10. Iwegbu CG, Fleming AF. Avascular necrosis of the femoral head in sicklecell disease. A series from the Guinea Savannah of Nigeria. J Bone Joint Surg Br 1985; 67: 29-32
11. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Pres 1993; 289: 136-143
12. Ware HE, Brooks AP, Toye R, et al. Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg Br 1991; 73: 947-949
13. Hernigou P, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle-cell disease. J Bone Joint Surg Am 2003; 85-A: 500-504
14. Hernigou P, Habibi A, Bachir D, et al. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am 2006; 88: 2565-2572
15. Hernigou P, Poignard A, Nogier A, et al. Fate of very small asymptomatic stage-I osteonecrotic lesions of the hip. J Bone Joint Surg Am 2004; 86-A: 2589-2593
16. Osunkwo I. An update on the recent literature on sickle cell bone disease. Curr Opin Endocrinal Diabetes Obes 2013; 20: 539-546
17. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010; 303: 1288-1294
18. Candrilli SD, O?Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 8: 273-277
19. Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84: 323-327
20. Lanzkron S, Haywood C Jr, Segal JB, et al. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006; 81: 927-932
21. Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol 2010; 85: 797-799
22. Okam MM, Shaykevich S, Ebert BL, et al. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. Med Care 2014; 52: 612-618
23. Ezenwa MO, Molokie RE, Wang ZJ, et al. Outpatient pain predicts subsequent one-year acute health care utilization among adults with sickle cell disease. J Pain Symptom Manage 2014; 48: 65-74
24. Savage WJ, Buchanan GR, Yawn BP, et al. Evidence gaps in themanagement of sickle cell disease: a summary of needed research. Am J Hematol 2015; 90: 273-275
25. Hawker H, Neilson H, Hayes RJ, et al. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. Br J Haematol 1982; 50: 29-34
26. Tripathy SK, Goyal T, Sen RK.Management of femoral head osteonecrosis: current concepts Indian J Orthop 2015; 49: 28-45
27. Johannson HR, Zywiel MG, Marker DR, et al. Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature review. Int Orthop 2011; 35: 465-473
28. Patel YD, Szczech BW, Patel S, et al. Management strategies for total hip arthroplasty in sickle cell patients. J Long Term Eff Med Implants 2014; 24: 219-224